A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Nov 2017 According to results published in the Journal of the American Society of Nephrology, a protocol was amended to reduce doses of 24 patients who initially received bosutinib at 400 mg/d to 200 mg/d.
    • 01 Nov 2017 Primary endpoint of annualized rate of kidney enlargement in patients treated for more than or equal to 2 weeks has been met, according to results published in the Journal of the American Society of Nephrology.
    • 01 Nov 2017 Results published in the Journal of the American Society of Nephrology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top